Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of vulvar malignancy
• * Stage I-IVB
• Planned radical vulvectomy or hemivulvectomy AND
• Ipsilateral or bilateral inguinal lymphadenectomy
• Presence of groin node metastases is allowed
• No primary or secondary lymphedema of the lower extremities
• PATIENT CHARACTERISTICS:
• Age:
• Over 18
• Performance status:
• GOG 0-3
• Life expectancy:
• Not specified
• Hematopoietic:
• Platelet count at least 100,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• No bleeding disorder
• Hepatic:
• Bilirubin no greater than 1.5 times normal
• SGOT no greater than 3 times normal
• Albumin at least 3.0 g/dL
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Cardiovascular:
• No prior lower extremity deep vein thrombosis
• Other:
• No known sensitivity or anaphylaxis to bovine-derived products
• No known prior exposure to fibrin tissue adhesive
• No other malignancy within the past 5 years except nonmelanoma skin cancer
• No nonhealing ulcer or chronic infection of the lower extremity, including superficial phlebitis
• No prior fracture of any portion of either leg
• Preoperative circumferential measurements of legs must differ by less than 3 cm
• Not pregnant or nursing
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• No prior chemotherapy for a prior malignancy
• Concurrent adjuvant chemotherapy allowed
• Endocrine therapy:
• Not specified
• Radiotherapy:
• No prior radiotherapy for a prior malignancy
• No prior radiotherapy to pelvis, abdomen, inguinal area, or lower extremity
• Surgery:
• See Disease Characteristics
• No prior inguinal surgery
• No prior surgery to veins or arteries of either leg
• No other concurrent elective surgery during same operative event as inguinal lymphadenectomy
• Other:
• At least 30 days since prior investigational products or devices
• At least 7 days since prior anticoagulants
• Concurrent enrollment on GOG-0173 or other adjuvant treatment protocols is allowed
• No other concurrent investigational products or devices